On ECHEMI
Home > Drugs > Haemophilus influenzae infection
Haemophilus influenzae infection
Hemophilus influenzae is a normal flora of the human upper respiratory tract. In the past, it has been mistaken for the pathogen of influenza, but in fact it has a wide range of pathogens. In addition to respiratory tract lesions, it can also cause meningitis, sepsis, conjunctivitis, female genital tract infection, cellulitis, etc. It is not only a common pathogen for infants and young children, but also one of the pathogens for adults. Vaccines can prevent serious diseases such as meningitis, sepsis, myelitis, otitis media, pericarditis, etc. caused by Haemophilus influenzae. It is most suitable for children under 5 years old.
  • Site of disease:

    Blood vessels lungs whole body
  • Infectious :

    Contagious
  • Frequent population:

    All groups
  • Related symptoms:

    Spasmodic cough sore throat fever spasmodic cough sore throat
  • Concurrent disease:

Related Drugs
DOXYCYCLINE HYCLATE- doxycycline hyclate_powder, for solution
Indication: Gram-Negative Bacteria
Acinetobacter Bartonella bacilliformis Brucella Enterobacter aerogenes Escherichia coli Francisella tularensis Haemophilus ducreyi Haemophilus influenzae Klebsiella granulomatis Klebsiella Neisseria gonorrhoeae Shigella species Vibrio cholerae Campylobacter fetus Yersinia pestis
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis The following gram-negative microorganisms: Haemophilus ducreyi Yersinia pestis. Francisella tularensis Bartonella bacilliformis Bacteroides Vibrio cholerae. Campylobacter fetus Brucella Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus Up to 44 percent of strains of Streptococcus pyogenes Enterococcus faecalis For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae Staphylococcus aureus Anthrax due to Bacillus anthracis Bacillus anthracis When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae N. meningitidis Treponema pallidum Treponema pertenue Listeria monocytogenes. Clostridium Fusobacterium fusiforme Actinomyces In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence.
Manufacturer:

Slate Run Pharmaceuticals, LLC

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.